← Centessa Pharmaceuticals PLC ADR overview

Centessa Pharmaceuticals PLC ADR vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Centessa Pharmaceuticals PLC ADR (CNTA)

Q2 2026
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

June 2026
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

Latest
▲4

Centessa's $7.8B Lilly Buyout Closes; Biotech M&A Boom Continues

  • UK court approves Lilly's $7.8B Centessa acquisition The UK High Court approved Eli Lilly's $7.8 billion buyout of Centessa. Shareholders get $38 per share in cash plus a contingent value right worth up to $9 more if milestones are met. This locked in the deal price and removed uncertainty, pushing CNTA toward the buyout value.

    This is the key regulatory approval that made the buyout final and set the exact payout for shareholders.

  • Lilly completes Centessa acquisition; CNTA delisted Eli Lilly closed its acquisition of Centessa on June 24, 2026. CNTA shares stopped trading on Nasdaq, and shareholders received the cash and CVR payout. This is the final step that turned the buyout into real money for investors.

    This is the event that ended CNTA's life as a public stock and delivered the buyout proceeds to shareholders.

  • Biopharma M&A hits six-year high, validating Centessa's sale PwC reported Q1 2026 pharma deal value topped $65 billion, the strongest since 2020, driven by a huge patent cliff. Lilly's $7.8 billion Centessa purchase was a highlight. This confirms Centessa was bought in a hot market, supporting the deal price and CVR potential.

    It shows the broader M&A boom that made Centessa's buyout possible and validates the valuation.

  • Biotech named hottest market group after Centessa deal Jim Cramer called biotech the hottest group, citing a 51% biotech ETF gain and a deal surge under new FDA leadership. He noted Lilly's acquisitions, including Centessa. This keeps investor attention on biotech M&A, which can lift CVR expectations and similar stocks.

    It reflects ongoing market enthusiasm for biotech deals, which supports the value of Centessa's CVR and the sector.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 2026
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest
▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

  • First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.

    The profit turnaround is the core fundamental change behind the stock's re-rating.

  • AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.

    A major global partnership is a new growth catalyst that directly lifts investor expectations.

  • New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.

    Regulatory progress on an existing product is a concrete new pipeline milestone.

  • Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.

    Institutional buying and supportive regulation are fresh demand and policy tailwinds.